183 related articles for article (PubMed ID: 22488176)
1. Risk of fracture with thiazolidinediones: disease or drugs?
Bazelier MT; Vestergaard P; Gallagher AM; van Staa TP; Cooper C; Leufkens HG; de Vries F
Calcif Tissue Int; 2012 Jun; 90(6):450-7. PubMed ID: 22488176
[TBL] [Abstract][Full Text] [Related]
2. Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?
Bazelier MT; Gallagher AM; van Staa TP; Cooper C; Leufkens HG; Vestergaard P; de Vries F
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):507-14. PubMed ID: 22392882
[TBL] [Abstract][Full Text] [Related]
3. Use of thiazolidinediones and risk of bladder cancer: disease or drugs?
Bazelier MT; de Vries F; Vestergaard P; Leufkens HG; De Bruin ML
Curr Drug Saf; 2013 Nov; 8(5):364-70. PubMed ID: 24215315
[TBL] [Abstract][Full Text] [Related]
4. Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.
Schwartz AV; Chen H; Ambrosius WT; Sood A; Josse RG; Bonds DE; Schnall AM; Vittinghoff E; Bauer DC; Banerji MA; Cohen RM; Hamilton BP; Isakova T; Sellmeyer DE; Simmons DL; Shibli-Rahhal A; Williamson JD; Margolis KL
J Clin Endocrinol Metab; 2015 Nov; 100(11):4059-66. PubMed ID: 26305617
[TBL] [Abstract][Full Text] [Related]
5. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
Driessen JH; van den Bergh JP; van Onzenoort HA; Henry RM; Leufkens HG; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):421-428. PubMed ID: 27943565
[TBL] [Abstract][Full Text] [Related]
6. Thiazolidinediones and fractures: evidence from translating research into action for diabetes.
Bilik D; McEwen LN; Brown MB; Pomeroy NE; Kim C; Asao K; Crosson JC; Duru OK; Ferrara A; Hsiao VC; Karter AJ; Lee PG; Marrero DG; Selby JV; Subramanian U; Herman WH
J Clin Endocrinol Metab; 2010 Oct; 95(10):4560-5. PubMed ID: 20631021
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.
Habib ZA; Havstad SL; Wells K; Divine G; Pladevall M; Williams LK
J Clin Endocrinol Metab; 2010 Feb; 95(2):592-600. PubMed ID: 20061432
[TBL] [Abstract][Full Text] [Related]
8. A cohort study of thiazolidinediones and fractures in older adults with diabetes.
Solomon DH; Cadarette SM; Choudhry NK; Canning C; Levin R; Stürmer T
J Clin Endocrinol Metab; 2009 Aug; 94(8):2792-8. PubMed ID: 19470635
[TBL] [Abstract][Full Text] [Related]
9. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
10. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
11. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.
Vallarino C; Perez A; Fusco G; Liang H; Bron M; Manne S; Joseph G; Yu S
Clin Drug Investig; 2013 Sep; 33(9):621-31. PubMed ID: 23881565
[TBL] [Abstract][Full Text] [Related]
12. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co-administration in patients with type 2 diabetes mellitus.
Ock M; Lee S; Kim H
J Clin Pharm Ther; 2022 Jul; 47(7):1028-1035. PubMed ID: 35257383
[TBL] [Abstract][Full Text] [Related]
14. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
15. Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients.
Chen HH; Horng MH; Yeh SY; Lin IC; Yeh CJ; Muo CH; Sung FC; Kao CH
PLoS One; 2015; 10(8):e0135530. PubMed ID: 26317995
[TBL] [Abstract][Full Text] [Related]
16. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
[TBL] [Abstract][Full Text] [Related]
17. Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.
Lin HC; Hsu YT; Kachingwe BH; Hsu CY; Uang YS; Wang LH
J Clin Pharm Ther; 2014 Aug; 39(4):354-60. PubMed ID: 24661226
[TBL] [Abstract][Full Text] [Related]
18. Use of thiazolidinediones and fracture risk.
Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR
Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256
[TBL] [Abstract][Full Text] [Related]
19. Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan.
Hsiao FY; Tsai YW; Wen YW; Chen PF; Chou HY; Chen CH; Kuo KN; Huang WF
Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):786-91. PubMed ID: 20607752
[TBL] [Abstract][Full Text] [Related]
20. Risk of fracture with thiazolidinediones: an individual patient data meta-analysis.
Bazelier MT; de Vries F; Vestergaard P; Herings RM; Gallagher AM; Leufkens HG; van Staa TP
Front Endocrinol (Lausanne); 2013; 4():11. PubMed ID: 23549934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
